Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
2024年8月13日 - 9:15PM
ビジネスワイヤ(英語)
Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an
innovation platform dedicated to discovering, developing, and
deploying promising innovations, announced the successful passage
of all proposals at its recent annual shareholders' meeting.
At the recent annual meeting, Aditxt shareholders approved all
nine proposals presented. These proposals equip Aditxt with the
necessary flexibility and potential resources to advance its
strategic initiatives.
- Election of Directors: Four board members were
re-elected, and one board member was elected to serve until the
2025 annual meeting, ensuring continuity in leadership.
- Ratification of Auditors: The reappointment of
dbbmckennon as the independent registered public accounting firm
for the fiscal year ending December 31, 2024, was ratified.
- Issuance of Shares for Series B-1 Convertible Preferred
Stock: Shareholders approved the issuance of common
stock underlying the Series B-1 Convertible Preferred Stock,
originally issued in January 2024.
- Issuance of Shares for Series B-2 Convertible Preferred
Stock: Similar approval was granted for the issuance of
common stock underlying the Series B-2 Convertible Preferred Stock,
also issued in January 2024.
- Equity Line of Credit (ELOC) Proposal: Approval was
given for the issuance of shares under the company’s equity line of
credit, allowing Aditxt to issue up to $150 million in common
stock.
- Authorized Share Increase: The number of authorized
shares of common stock was increased from 100,000,000 to
1,000,000,000, providing flexibility for future financing and
growth.
- Reverse Stock Split Proposal: The board was granted
discretionary authority to execute a reverse stock split, ranging
from one-for-five (1:5) to one-for-two hundred (1:200).
- Amendment to the 2021 Omnibus Equity Incentive Plan (the
“2021 Plan”): The 2021 Plan was amended to increase the number of
shares issuable under the 2021 Plan to 500,000 from the previous
37,500 shares.
- Adjournment Proposal: The proposal authorized the
adjournment of the meeting if necessary, to solicit additional
votes to approve any proposal.
Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt,
emphasized, “I want to thank all of our stakeholders for their
participation and continued support. We believe that the approval
of these proposals will equip us with important tools as we
continue to work on meeting certain of our existing obligations and
position Aditxt towards achieving our strategic initiatives.”
Aditxt operates two programs (through two subsidiaries, Adimune,
Inc. and Pearsanta, Inc.) focused on immune health and precision
health, respectively. Following the completion of the Appili
Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) and Evofem
Biosciences, Inc. (OTCQB: EVFM) transactions, Aditxt will introduce
two additional programs; one program will be dedicated to public
health and the other program will be dedicated to women's health.
Each program is designed to function autonomously while
collectively advancing Aditxt’s mission of discovering, developing,
and deploying innovative health solutions to tackle some of the
most urgent health challenges. The closing of each of these
transactions is subject to several conditions, including but not
limited to approval of the transactions by the respective target
shareholders and Aditxt raising sufficient capital to fund the
Company’s obligations at closing. No assurance can be provided that
all of the conditions to closing will be obtained or satisfied or
that either of the transactions will ultimately close.
About Aditxt, Inc.
Aditxt, Inc.® is an innovation platform dedicated to
discovering, developing, and deploying promising innovations.
Aditxt’s ecosystem of research institutions, industry partners, and
shareholders collaboratively drives their mission to “Make
Promising Innovations Possible Together.” The innovation platform
is the cornerstone of Aditxt’s strategy, where multiple disciplines
drive disruptive growth and address significant societal
challenges. Aditxt operates a unique model that democratizes
innovation, ensures every stakeholder’s voice is heard and valued,
and empowers collective progress.
Aditxt has a diverse innovation portfolio, including Adimune™,
Inc., which is leading the charge in developing a novel class of
therapeutics for retraining the immune system to combat organ
rejection, autoimmunity, and allergies. Adivir™, Inc. focuses on
enhancing national and population health and impacting public
health globally. Pearsanta™, Inc., delivers rapid, personalized,
and high-quality lab testing accessible anytime, anywhere, led by
its CLIA-certified and CAP-accredited clinical laboratory based in
Richmond, VA.
For more information, www.aditxt.com.
Follow us on: Linkedin: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s ability to finance and execute on its strategic
M&A initiatives; the Company’s ability obtain the necessary
funding and partner to commence clinical trials; the Company’s
intellectual property position; the Company’s ability to develop
commercial functions; expectations regarding product launch and
revenue; the Company’s results of operations, cash needs, spending,
financial condition, liquidity, prospects, growth and strategies;
the Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240813733227/en/
Media Relations: Mary O’ Brien mobrien@aditxt.com (516)
753-9933
Aditxt (NASDAQ:ADTX)
過去 株価チャート
から 8 2024 まで 9 2024
Aditxt (NASDAQ:ADTX)
過去 株価チャート
から 9 2023 まで 9 2024